Osteoarthritis doesn’t just wear down cartilage and make joints stiff. In a substantial number of people, it also produces nerve-related pain that burns, shoots, or tingles in ways that typical joint ache does not. A meta-analysis of knee osteoarthritis studies found that roughly 20 to 40 percent of patients show signs of neuropathic-like pain, depending on the screening tool used. That figure matters because nerve pain responds poorly to standard painkillers like anti-inflammatories and often requires a different treatment strategy altogether.
Why Osteoarthritis Produces Nerve-Like Pain
The classic textbook picture of osteoarthritis focuses on cartilage breakdown, bone-on-bone contact, and inflammation in the joint lining. That picture is real but incomplete. As the disease progresses, the inflamed joint releases a cascade of chemical signals that directly affect nearby sensory nerves. One of the most studied of these signals is nerve growth factor, or NGF. Damaged cartilage cells and the inflamed tissue lining the joint ramp up NGF production in response to inflammatory molecules. NGF then does two things you don’t want: it makes existing nerve endings hypersensitive, and it coaxes nerve fibers to sprout into tissues where they normally don’t belong, including damaged cartilage and bone.
Animal and laboratory studies show that elevated NGF activates a receptor on nerve endings that controls pain-sensing ion channels and neuropeptides, amplifying pain signals at their source. The result is a joint whose wiring has been remodeled by disease, with nerve endings that fire more easily and in more locations than they would in a healthy knee or hip. Synovial fluid and blood samples from people with osteoarthritis consistently show elevated NGF, and those levels track with disease severity.
Beyond NGF, pro-inflammatory cytokines produced during joint breakdown directly sensitize nerve fibers. A study of end-stage knee osteoarthritis patients found that interleukin-6 levels in synovial fluid were significantly associated with neuropathic pain features, and that synovitis was an important factor linking tissue-breakdown biomarkers to nerve-related pain symptoms.
Central Sensitization and How Pain Spreads Beyond the Joint
The nerve changes in osteoarthritis aren’t limited to the joint itself. Over time, persistent pain signaling from an arthritic knee or hip can rewire pain-processing circuits in the spinal cord and brain, a phenomenon called central sensitization. When this happens, the nervous system essentially turns up its volume knob: stimuli that shouldn’t be painful become painful, and stimuli that are mildly painful become excruciating.
A systematic review and meta-analysis found clear evidence that pain sensitization is present in people with knee osteoarthritis and is linked to the severity of their symptoms. Preclinical research has confirmed that spinal nociceptive reflex pathways become sensitized after osteoarthritis develops, along with changes in the brain’s descending pain-control systems that normally help dampen pain signals. In practical terms, this means that the amount of structural damage visible on an X-ray often doesn’t match how much pain a person feels. Someone with moderate cartilage loss can be in agony, while someone with severe joint damage might report only mild discomfort. Central sensitization is one of the main reasons for that mismatch.
People with knee osteoarthritis who undergo standardized sensory testing tend to show lower pressure pain thresholds, impaired ability to suppress incoming pain signals, and an exaggerated pain response to repeated stimuli, compared with people without osteoarthritis. These findings hold up across multiple studies and support the idea that the nervous system’s pain-processing machinery is genuinely altered in many osteoarthritis patients.
What Nerve Pain Feels Like Compared to Typical Joint Pain
Ordinary osteoarthritis pain tends to be a deep, dull ache that worsens with activity and improves with rest, at least early on. Nerve-related osteoarthritis pain has a distinctly different character. People describe burning sensations in or around the joint, sharp shooting pains that radiate beyond the joint line, pins-and-needles tingling, and painful sensitivity to light touch or pressure that shouldn’t hurt. Some experience a strange numbness alongside the pain, which can be confusing since you’d expect numbness and pain to be opposites.
These neuropathic features, including allodynia (pain from normally harmless touch) and hyperalgesia (exaggerated pain from mildly painful stimuli), arise from aberrant nerve growth, nerve injury, and altered pain processing in both the peripheral and central nervous systems. The combination means that pulling on a sock, resting a knee against a mattress, or even a light breeze across the skin near the joint can trigger real pain. This is qualitatively different from the mechanical ache of bone rubbing on bone, and recognizing the distinction is the first step toward getting appropriate treatment.
How Common Is the Nerve Component
Estimates vary depending on the screening questionnaire used and the population studied, but the numbers are consistently higher than most people expect. A large meta-analysis pooling data from multiple studies of knee osteoarthritis found that about 40 percent of patients screened positive for possible neuropathic pain on the PainDETECT questionnaire, and about 20 percent hit the threshold for probable neuropathic pain. Using a different validated tool, the DN4 questionnaire, roughly 41 percent screened positive. A separate meta-analysis focusing on osteoarthritis more broadly reported a pooled neuropathic pain prevalence of about 28 percent. A cross-sectional study of primary knee osteoarthritis patients found even higher rates, with over half screening positive on both the DN4 and PainDETECT tools.
These are not small minorities. Women appear to be disproportionately affected, with one analysis reporting that roughly 85 percent of osteoarthritis patients with neuropathic pain were women, though the confidence interval on that estimate was wide. The takeaway is that nerve-related pain is not a rare complication of osteoarthritis. It’s a common feature that is underrecognized partly because clinicians and patients alike tend to attribute all osteoarthritis pain to joint damage alone.
How Clinicians Identify the Nerve Component
There is no blood test or imaging scan that definitively diagnoses neuropathic pain in osteoarthritis. Instead, clinicians rely on validated screening questionnaires and, in research settings, quantitative sensory testing. The two most widely used questionnaires are the PainDETECT and the DN4. Each asks patients about the quality of their pain (burning, shooting, tingling, numbness) and, in the case of the DN4, includes a brief physical exam checking for reduced sensation and pain from light touch. A study comparing the two tools found that they agreed on classification about 78 percent of the time, which is reasonable but not perfect.
Quantitative sensory testing goes a step further by measuring how the nervous system responds to controlled stimuli like pressure, heat, or repeated tapping. A systematic review found that the most commonly used measures are pressure pain thresholds, conditioned pain modulation (how well the body’s natural pain-dampening system works), and temporal summation (whether pain builds up with repeated stimulation). Compared with people without osteoarthritis, those with knee osteoarthritis consistently show lower pressure pain thresholds and less effective pain modulation. These tests aren’t routine in most clinics, but they can be valuable when the standard approach to pain management isn’t working and a clinician wants to understand whether central sensitization is playing a role.
Why Standard Painkillers Often Fall Short
The most common first-line treatments for osteoarthritis pain, including acetaminophen, oral anti-inflammatories, and joint injections of corticosteroids or hyaluronic acid, primarily target inflammation and nociceptive (tissue-damage) pain. If a significant portion of your pain is coming from sensitized or remodeled nerves, these treatments are addressing only part of the problem. This helps explain why some people with osteoarthritis get modest or no relief from medications that work well for others with similar-looking joints on X-ray.
Recognizing the nerve component doesn’t mean abandoning anti-inflammatories. Joint inflammation feeds nerve sensitization, so reducing inflammation still helps. But it does mean that adding treatments that specifically target nerve pain pathways can make a meaningful difference for the subset of patients whose pain has a neuropathic character.
Medications That Target the Nerve Component
Duloxetine is the best-studied medication for nerve-related osteoarthritis pain. It works by increasing levels of serotonin and norepinephrine in the spinal cord, strengthening the body’s descending pain-inhibition pathways that central sensitization has weakened. A systematic review and meta-analysis of nine randomized controlled trials found that duloxetine produced a statistically significant reduction in average pain scores compared with placebo, along with meaningful improvements in physical function and patient-reported quality of life. The pain reduction was moderate in size, not dramatic, but consistent across studies and clinically relevant for many patients. Duloxetine was also associated with more side effects than placebo, including nausea, fatigue, and constipation, though serious adverse events were not significantly different from placebo.
Pregabalin, a medication originally developed for seizures and later approved for several neuropathic pain conditions, has shown promise in hand osteoarthritis. In a clinical trial, pregabalin significantly reduced pain scores and improved hand function compared with placebo. The most common side effects were mental disturbance, headaches, sleepiness, and dizziness. Evidence for pregabalin in knee or hip osteoarthritis is thinner, and it is not as widely used for this purpose as duloxetine.
Topical lidocaine patches offer a more localized option. A pilot study of patients with moderate-to-severe knee osteoarthritis found that two weeks of treatment with a 5% lidocaine patch significantly reduced the intensity of pain qualities measured on a neuropathic pain scale. Because the medication stays mostly at the skin and joint surface rather than circulating through the body, side effects tend to be limited to local skin irritation. Lidocaine patches can be a useful add-on for people who can’t tolerate systemic medications or who want to avoid oral drugs.
Radiofrequency Ablation of Genicular Nerves
For people whose knee pain hasn’t responded adequately to medications and physical therapy, and who either aren’t ready for or aren’t candidates for joint replacement, genicular nerve radiofrequency ablation has become an increasingly popular option. The procedure uses heat delivered through a needle to disable the small sensory nerves that transmit pain signals from the knee joint to the brain. It doesn’t fix the underlying arthritis, but it can substantially reduce the pain signal.
Studies consistently show short-term pain relief lasting three to six months, and sometimes longer. One case series reported a mean pain score reduction of about 50 percent at two weeks and 55 percent at four to six weeks, with an average total duration of relief of roughly nine months. A randomized clinical trial comparing radiofrequency ablation with platelet-rich plasma injections found that ablation produced significantly better pain scores at six and twelve months.
The procedure can be repeated in patients who respond well, since the ablated nerves eventually regenerate. It has a strong safety profile, with complications being rare. Ablation of the nerves serving different quadrants of the knee, including the less commonly targeted inferolateral region, appears to be equally safe and effective. For patients who get good relief, this procedure can serve as a bridge, buying months or even a year of reduced pain while they strengthen the muscles around the joint or wait for the right time for surgery.
Exercise, Electrical Stimulation, and Other Non-Drug Approaches
Exercise remains one of the most consistently recommended treatments for osteoarthritis pain in general, and emerging evidence suggests it may specifically help with the nerve-related component. An animal study of end-stage knee osteoarthritis found that low-intensity muscle contraction exercise reduced pain sensitivity by modifying both peripheral joint pathology and central sensitization, even without improving cartilage or bone damage. The implication is that exercise doesn’t need to reverse structural damage to help with nerve pain; it can work by calming down the overactive pain-processing system.
Transcutaneous electrical nerve stimulation, or TENS, has mixed evidence in the context of central sensitization. A randomized trial comparing TENS with interferential current therapy and sham treatment found that TENS significantly improved pressure pain thresholds at both two weeks and three months, with the improvement being more pronounced in the TENS group than in the other groups. However, there is a theoretical concern that in patients who are already centrally sensitized, electrical stimulation of skin nerves could paradoxically enhance the responsiveness of overexcited spinal pain neurons. In practice, most patients tolerate TENS well, but clinicians who suspect strong central sensitization may want to monitor the response carefully rather than assuming benefit.
Dietary patterns have also drawn attention. An umbrella review of the evidence found that the Mediterranean diet had the strongest support for improving osteoarthritis-related outcomes, including pain, stiffness, and markers of inflammation and cartilage breakdown. The effects are modest and indirect, working through reduced systemic inflammation rather than any direct nerve mechanism, but since inflammation is a key driver of nerve sensitization in osteoarthritis, anti-inflammatory eating patterns can be a sensible complement to other treatments.
When Joint Replacement Doesn’t Fix the Pain
Total knee replacement is often presented as the definitive solution for severe osteoarthritis. For many people it is. But a meaningful minority continue to have significant pain after surgery, and nerve-related pain is a major reason why. A study tracking patients after total knee arthroplasty found that among those reporting chronic pain at three months, roughly half had neuropathic pain features on the PainDETECT questionnaire and about three-quarters screened positive on the DN4. Of those with neuropathic pain at three months, more than half still had symptoms a year later.
Broader reviews of the literature report that persistent post-surgical pain affects anywhere from 13 to 39 percent of patients at six to twelve months after knee replacement, and neuropathic pain specifically is found in roughly 5 to 13 percent at six months. These numbers are sobering for anyone assuming that surgery will eliminate their pain entirely.
The reasons for post-surgical nerve pain include direct nerve injury during the operation (the skin incision inevitably cuts small nerve branches), inflammation during healing, and pre-existing central sensitization that the surgery doesn’t address. If the nervous system was already in a state of heightened pain processing before surgery, removing the damaged joint doesn’t automatically reset that system. This is one argument for identifying and managing the nerve pain component before surgery when possible, since patients who go into the operating room with less central sensitization may have better outcomes afterward.
How Osteoarthritis Nerve Pain Affects Work and Daily Life
The practical burden of nerve-related osteoarthritis pain extends well beyond the clinic. Burning, shooting, and touch-sensitive pain can disrupt sleep in ways that a predictable mechanical ache does not, since nerve pain often flares at rest or with light contact from bedding. An online survey of over a thousand people with osteoarthritis found that 61 percent of those still working reported they might have to retire early because of their condition, 19 percent had already reduced their hours, and 17 percent had already retired early. While this survey covered osteoarthritis pain broadly and not just the neuropathic subtype, the people most likely to be driven out of work are those whose pain is the most treatment-resistant, and unrecognized nerve pain is a common reason treatments don’t work as expected.
For people dealing with this kind of pain, the practical message is worth knowing: if your osteoarthritis pain burns, shoots, tingles, or makes your skin feel painfully sensitive to touch, bring those specific descriptors to your clinician. Many people instinctively downplay unusual pain qualities or assume they’re just part of arthritis. But those details are exactly what helps a clinician identify whether a nerve-targeted treatment might help, whether that’s duloxetine, a TENS unit, radiofrequency ablation, or simply a better understanding of what’s going on inside the joint.
The Role of Synovitis and Inflammation in Driving Nerve Symptoms
One of the more clinically useful insights from recent research is that synovitis, the inflammation of the tissue lining the joint capsule, appears to be a key bridge between structural joint damage and nerve pain. A study of end-stage knee osteoarthritis patients found that a biomarker of tissue remodeling (C1M) and interleukin-6 in synovial fluid were both associated with neuropathic pain features, but the relationship was confounded by synovitis. In other words, it wasn’t just that damaged tissue was releasing chemicals that irritated nerves; it was that the inflamed synovium was acting as a mediator, amplifying and transmitting the pain-generating signals from damaged cartilage and bone to nearby nerve endings.
This finding has treatment implications. Interventions that specifically target synovitis, whether through intra-articular corticosteroid injections, anti-inflammatory medications, or even targeted physical therapy, may help reduce the nerve pain component indirectly by quieting the inflammatory environment that drives nerve sensitization. It also suggests that the common clinical observation of osteoarthritis patients whose pain suddenly worsens during a “flare” may partly reflect a spike in synovial inflammation that tips sensitized nerves into a more active pain state. Addressing flares aggressively, rather than waiting them out, could help prevent the cycle of inflammation, nerve sensitization, and central pain amplification from ratcheting up further.